Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AK112 + short-course radiotherapy + capecitabine + oxaliplatin
- Development stage
- Phase 2
- Lead developer
- Kangfang Sainuo Pharmaceutical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems
- Administration
- Oral, Intravenous
01
Overview
This is a combination therapy regimen consisting of AK112 (a PD-1/VEGF bispecific antibody), short-course radiotherapy (SCRT), and the chemotherapy combination of capecitabine and oxaliplatin (CAPOX). This regimen is being investigated as a neoadjuvant therapy for locally advanced rectal cancer. The treatment protocol typically involves administering short-course radiotherapy followed by AK112 in combination with CAPOX chemotherapy.
- Other names
- AK112 + SCRT + capecitabine + oxaliplatinAK112 + SCRT + CAPOX
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on AK112 + short-course radiotherapy + capecitabine + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AK112 + short-course radiotherapy + capecitabine + oxaliplatin.